Is Ascletis Pharma (SEHK:1672) Undervalued As FDA Clears Its ASC35 Obesity Trial?

Simply Wall St.07-06 13:22

Ascletis Pharma (SEHK:1672) recently received U.S. FDA Investigational New Drug clearance to begin a Phase I trial of ASC35, a once monthly GLP-1R/GIPR dual agonist for obesity treatment. See our ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2649676647?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-07-06 13:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2649676647","market":"hk","top_or_hot":-1,"title":"Is Ascletis Pharma (SEHK:1672) Undervalued As FDA Clears Its ASC35 Obesity Trial?","media":"Simply Wall St.","content":"<div>\n<p>Ascletis Pharma (SEHK:1672) recently received U.S. FDA Investigational New Drug clearance to begin a Phase I trial of ASC35, a once monthly GLP-1R/GIPR dual agonist for obesity treatment. See our ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1672/ascletis-pharma-shares/news/is-ascletis-pharma-sehk1672-undervalued-as-fda-clears-its-as\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Ascletis Pharma (SEHK:1672) Undervalued As FDA Clears Its ASC35 Obesity Trial?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Ascletis Pharma (SEHK:1672) Undervalued As FDA Clears Its ASC35 Obesity Trial?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-06 13:22 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1672/ascletis-pharma-shares/news/is-ascletis-pharma-sehk1672-undervalued-as-fda-clears-its-as><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Ascletis Pharma (SEHK:1672) recently received U.S. FDA Investigational New Drug clearance to begin a Phase I trial of ASC35, a once monthly GLP-1R/GIPR dual agonist for obesity treatment. See our ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1672/ascletis-pharma-shares/news/is-ascletis-pharma-sehk1672-undervalued-as-fda-clears-its-as\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1515","symbol_name":"抗疫概念","start_time":0,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1672/ascletis-pharma-shares/news/is-ascletis-pharma-sehk1672-undervalued-as-fda-clears-its-as","article_id":"2649676647","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1672/ascletis-pharma-shares/news/is-ascletis-pharma-sehk1672-undervalued-as-fda-clears-its-as","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2649676647","pubTimestamp":1783315338,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Ascletis Pharma (SEHK:1672) recently received U.S. FDA Investigational New Drug clearance to begin a Phase I trial of ASC35, a once monthly GLP-1R/GIPR dual agonist for obesity treatment.\nSee our latest analysis for Ascletis Pharma.\nAt a latest share price of HK$11.54, Ascletis Pharma has seen a 7 day share price return of 18.72% and a 30 day share price return of 10.11%. However, the 90 day share price return is down 32.04%. The 1 year total shareholder return of 22.51% and the very large 3...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1515":"抗疫概念","LABU":"三倍做多标普生物-Direxion","01672":"歌礼制药-B","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK1161":"生物科技","BK1574":"生物医药B类股"},"translate_title":"FDA批准歌礼制药（SEHK：1672）的ASC35肥胖试验是否被低估？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01672":1.5,"LABU":1.5},"content_text":"Ascletis Pharma (SEHK:1672) recently received U.S. FDA Investigational New Drug clearance to begin a Phase I trial of ASC35, a once monthly GLP-1R/GIPR dual agonist for obesity treatment. See our latest analysis for Ascletis Pharma. At a latest share price of HK$11.54, Ascletis Pharma has seen a 7 day share price return of 18.72% and a 30 day share price return of 10.11%. However, the 90 day share price return is down 32.04%. The 1 year total shareholder return of 22.51% and the very large 3 year and 5 year total shareholder returns suggest longer term holders have seen substantial gains, with the recent FDA IND clearance for ASC35 likely feeding into shifting expectations around growth potential and risk. If news around obesity treatments has caught your attention, it may be a good time to see what else is moving and check out 133 healthcare AI stocks With Ascletis Pharma now trading at HK$11.54 against an analyst price target of HK$24.01, the question for investors is simple: is this obesity pipeline still undervalued or is future growth already in the price? AdvertisementPreferred Price-to-Book Multiple of 5.5x: Is It Justified? With Ascletis Pharma last trading at HK$11.54, investors are paying a P/B ratio of 5.5x, which is described as expensive compared to the Hong Kong Biotechs industry average of 3.4x, but cheaper than a much higher peer average of 81.2x. The price to book ratio compares a company’s market value to its net assets on the balance sheet. This can be a common reference point for early stage or loss making biotechs where earnings are not yet positive. For Ascletis Pharma, a 5.5x P/B suggests the market is assigning a premium to the current asset base, reflecting expectations around the pipeline, including projects such as ASC35 for obesity and other programs across hepatitis, oncology and metabolic disease. Relative to the broader Hong Kong Biotechs industry, Ascletis Pharma’s P/B is higher than the 3.4x average. This points to investors pricing in stronger potential or a different risk and return profile compared to typical peers. At the same time, the ratio is described as good value against a peer group P/B of 81.2x, which indicates that, within a set of higher priced biotech stocks, Ascletis sits at the lower end of the valuation range on this metric. See what the numbers say about this price — find out in our valuation breakdown. Result: Price-to-book of 5.5x (ABOUT RIGHT) However, investors in Ascletis Pharma still face clear risks, including annual revenue and net income declines, as well as heavy dependence on a single, early stage obesity pipeline. Find out about the key risks to this Ascletis Pharma narrative. Next Steps Given the mix of excitement around Ascletis Pharma and the clear risks on the table, it makes sense to move quickly and review the details for yourself, starting with the 2 important warning signs. Looking for more investment ideas beyond Ascletis Pharma? If Ascletis Pharma has you rethinking what belongs in your portfolio, do not stop here. Broaden your watchlist with a few hand picked stock ideas before the next move.  Target dependable cash generators by reviewing companies in the solid balance sheet and fundamentals stocks screener (418 results) that pair stronger finances with clearer fundamentals. Hunt for potential mispricings by checking stocks in the screener containing 498 high quality undiscovered gems that may not be on every investor’s radar yet. Prioritise resilience by scanning the 294 resilient stocks with low risk scores that focuses on stocks with lower risk scores to help steady your overall portfolio.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2649676647","isCrawlerRequest":true}